ARCHIVES

Advanced Ovarian Cancer Responds To Irofulven In Phase II Studies

This article is from The Cancer Letter archive.

Vol. 24 No. 10 | October 26, 2001

Download PDF Visit The Full Archive

Related Articles

FDA Continues Bureaucratic Delays Of Cancer INDs

January 30, 1976

DCCP Board Okays New, Recompeting Contracts Worth $4.6 Million In ‘81

October 17, 1980

ASCO Annual Meeting: PARP Inhibitors Show Promise Against Breast Cancer In Small Phase II Studies

June 5, 2009

Deals & Collaborations: UAB To Evaluate Firm’s Prostate Cancer Treatment

June 1, 2001

PRI Asks NIH To Cancel Recompetition Of Frederick Center Operations Contract

February 17, 1995

NCAB Study Core Guideline Revisions; Final Decision To Await New Division BSC

May 23, 1980